诊断学理论与实践 ›› 2023, Vol. 22 ›› Issue (03): 277-282.doi: 10.16150/j.1671-2870.2023.03.11
收稿日期:
2023-05-05
出版日期:
2023-06-25
发布日期:
2023-11-17
通讯作者:
孙杰 E-Mail: WEI Jian1, SUN Jie2(), CUI Shishuang3,4()
Received:
2023-05-05
Online:
2023-06-25
Published:
2023-11-17
摘要:
目的:构建帕金森病(Parkinson’s disease, PD)早期诊断诺谟图模型并验证。方法:本研究连续纳入2013年6月至2019年12月期间在上海交通大学附属瑞金医院住院的PD患者201例(PD组),以同期住院的201例神经系统慢性疾病患者非原发性帕金森病作为对照(非PD组)。在402例研究对象中,分层随机抽取300例(PD患者和非PD患者各150例)作为训练集,其余102例(PD患者51例,非PD患者51例)作为验证集。本研究采用具有完整数据处理、计算和制图能力的R软件(4.2.1版本)对训练集进行数据分析,采用单因素回归分析筛选PD的危险因素,并进一步进行多因素logistic回归分析及列线图模型构建。利用校准曲线受试者操作特征曲线分别对训练集和验证集进行内部及外部验证。结果:多因素logistic回归分析显示,高龄(>60岁)(OR=3.987,95%CI为2.126~7.477,P=0.131)、认知功能障碍蒙特利尔认知评估量表(Montreal Cognitive Assessment,MoCA)评分>26)(OR=3.094,95%CI为1.654~5.787,P<0.001)、便秘(OR=2.630,95%CI为1.430~4.835,P=0.002)、快速眼动睡眠行为障碍(rapid-eye-movement sleep behavior disorder, RBD)(OR=2.710,95%CI为1.449~5.068,P=0.002)、嗅觉减退(OR=2.117,95%CI为1.172~3.824,P=0.013)、铜兰蛋白(<20 mg/L)(ceruloplasmin,CER)水平降低(OR=3.356,95%CI为1.923~5.855,P<0.001)是PD的危险因素。基于上述危险因素建立诺谟图模型,内外部验证曲线下面积分别为0.729、0.714。结论:诺谟图诊断模型能有效辅助诊断PD,具有一定的临床应用价值。
中图分类号:
魏坚, 孙杰, 崔诗爽. 帕金森病早期诊断诺谟图模型的建立及验证[J]. 诊断学理论与实践, 2023, 22(03): 277-282.
WEI Jian, SUN Jie, CUI Shishuang. Development of a Nomogram model for early diagnosis of Parkinson disease[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(03): 277-282.
表1
训练集与验证集资料[n(%)]
Characteristics | Training set (n=300) | Validation set (n=102) | P value |
---|---|---|---|
Gender | 0.633 | ||
Female | 167 (41.5%) | 54 (13.4%) | |
Male | 133 (33.1%) | 48 (11.9%) | |
Agedness | 0.278 | ||
Yes | 219 (54.5%) | 80 (19.9%) | |
No | 81 (20.1%) | 22 (5.5%) | |
diabetes | 0.310 | ||
Yes | 38 (9.5%) | 17 (4.2%) | |
No | 262 (65.2%) | 85 (21.1%) | |
Cognitive decline | 0.830 | ||
Yes | 218 (54.2%) | 73 (18.2%) | |
No | 82 (20.4%) | 29 (7.2%) | |
RBD | 0.840 | ||
Yes | 212 (52.7%) | 71 (17.7%) | |
No | 88 (21.9%) | 31 (7.7%) | |
Constipation | 0.814 | ||
Yes | 214 (53.2%) | 74 (18.4%) | |
No | 86 (21.4%) | 28 (7%) | |
Hyposmia | 0.136 | ||
Yes | 212 (52.7%) | 64 (15.9%) | |
No | 88 (21.9%) | 38 (9.5%) | |
CER | 195.95 (±15.15) | 202 (±51.42) | 0.109 |
Hypertension | 0.440 | ||
Yes | 38 (9.5%) | 16 (4%) | |
No | 262 (65.2%) | 86 (21.4%) | |
Postural hypotension | 0.542 | ||
Yes | 238 (59.2%) | 78 (19.4%) | |
No | 62 (15.4%) | 24 (6%) | |
Smoking | 0.570 | ||
Yes | 73 (18.2%) | 22 (5.5%) | |
No | 227 (56.5%) | 80 (19.9%) | |
Drinking | 0.333 | ||
Yes | 76 (18.9%) | 21 (5.2%) | |
No | 224 (55.7%) | 81 (20.1%) |
表2
PD危险因素单因素回归分析
Characteristics | OR | 95% CI | P value |
---|---|---|---|
Gender | 0.703 | 0.445-1.111 | 0.131 |
Agedness | 2.979 | 1.732-5.122 | <0.001 |
Diabetes | 1.274 | 0.643-2.523 | 0.488 |
Cognitive decline | 2.280 | 1.348-3.856 | 0.002 |
RBD | 1.919 | 1.156-3.187 | 0.012 |
Constipation | 2.383 | 1.418-4.005 | <0.001 |
Hyposmia | 1.795 | 1.083-2.975 | 0.023 |
CER | 2.389 | 1.477-3.866 | <0.001 |
Hypertension | 0.785 | 0.396-1.556 | 0.488 |
Postural hypotension | 1.562 | 0.890-2.741 | 0.120 |
Smoking | 1.296 | 0.759-2.211 | 0.342 |
Drinking | 0.732 | 0.422-1.268 | 0.266 |
表3
PD危险因素多因素回归分析
Characteristics | regression coefficient | OR | OR(95% CI) | P value |
---|---|---|---|---|
Agedness | 1.228 | 3.413 | 1.884 - 6.182 | <0.001 |
Cognitive decline | 0.951 | 2.588 | 1.444 - 4.642 | <0.001 |
RBD | 0.665 | 1.945 | 1.090- 3.471 | 0.024 |
Constipation | 1.064 | 2.897 | 1.623 - 5.169 | <0.001 |
Hyposmia | 0.751 | 2.120 | 1.208 - 3.722 | 0.009 |
CER | 1.211 | 3.356 | 1.923 - 5.855 | <0.001 |
[1] |
BLOEM B R, OKUN M S, KLEIN C. Parkinson's disease[J]. Lancet, 2021, 397(10291):2284-2303.
doi: 10.1016/S0140-6736(21)00218-X pmid: 33848468 |
[2] |
ARMSTRONG M J, OKUN M S. Diagnosis and treatment of Parkinson disease: a review[J]. JAMA, 2020, 323(6):548-560.
doi: 10.1001/jama.2019.22360 pmid: 32044947 |
[3] |
HAYES M T. Parkinson's Disease and Parkinsonism[J]. Am J Med, 2019, 132(7):802-807.
doi: S0002-9343(19)30235-9 pmid: 30890425 |
[4] |
CEBALLOS-BAUMANN A. Parkinson-Syndrom [Parkinson's Disease - What is New?][J]. Dtsch Med Wochenschr 2022, 147(6):337-343.
doi: 10.1055/a-1646-6321 URL |
[5] | DORSEY E R, SHERER T, OKUN M S, et al. The emerging evidence of the Parkinson pandemic[J]. J Parkinsons Dis, 2018, 8(s1):S3-S8. |
[6] |
TONG C, MIAO Q, ZHENG J, et al. A novel nomogram for predicting the decision to delayed extubation after thoracoscopic lung cancer surgery[J]. Ann Med, 2023, 55(1):800-807.
doi: 10.1080/07853890.2022.2160490 pmid: 36869647 |
[7] |
ABDULHALEEM M, RUIZ J, CRAMER C, et al. Brain metastasis prognostic nomograms and brain metastasis velocity: a narrative review[J]. Chin Clin Oncol, 2022, 11(2):10.
doi: 10.21037/cco URL |
[8] |
ZHANG L, TANG L, CHEN S, et al. A nomogram for predicting the 4-year risk of chronic kidney disease among Chinese elderly adults[J]. Int Urol Nephrol, 2023, 55(6):1609-1617.
doi: 10.1007/s11255-023-03470-y |
[9] | 石红, 杨彦辉, 张亚萍, 等. Nomogram预测乳腺浸润性导管癌Ki-67表达水平[J]. 中国超声医学杂志, 2023, 39(1):17-21. |
SHI H, YANG Y H, ZHANG Y P, et al. Nomogram to Predict Ki-67 Expression levels in invasive ductal breast cancer[J]. Chin J Ultrasound Med, 2023, 39(1):17-21. | |
[10] |
YE H, ROBAK L A, YU M, et al. Genetics and Pathoge-nesis of Parkinson's Syndrome[J]. Annu Rev Pathol, 2023, 18:95-121.
doi: 10.1146/pathmechdis.2023.18.issue-1 URL |
[11] | 王刚, 崔海伦. 帕金森病临床诊断和治疗现状及进展[J]. 重庆医科大学学报, 2019, 44(4):464-467. |
WANG G, CUI H L. Clinical diagnosis and treatment of Parkinson's disease in China:Current status and research advances[J]. J Chongqing Med Univ, 2019, 44(4):464-467. | |
[12] | 孙雪婷, 张志伟, 余刚. 磁敏感加权成像黑质“燕尾征”在帕金森病中的诊断价值[J]. 重庆医科大学学报, 2021, 46(7):823-827. |
SUN X T, ZHANG Z W, YU G. Diagnostic value of “swallow tail” appearance in the substantia nigra using susceptibility weighted imaging in Parkinson's disease[J]. J Chongqing Med Univ, 2021, 46(7):823-827. | |
[13] |
AMBROSIO L, PORTILLO M C, RODRIGUEZ-BLAZQUEZ C, et al. Influencing factors when living with Parkinson's disease: a cross-sectional study[J]. J Clin Nurs, 2019, 28(17-18):3168-3176.
doi: 10.1111/jocn.14868 pmid: 30938889 |
[14] |
SIMON D K, TANNER C M, BRUNDIN P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology[J]. Clin Geriatr Med, 2020, 36(1):1-12.
doi: S0749-0690(19)30063-1 pmid: 31733690 |
[15] |
PAN L, LI C, MENG L, et al. Tau accelerates α-synuclein aggregation and spreading in Parkinson's disease[J]. Brain, 2022, 145(10):3454-3471.
doi: 10.1093/brain/awac171 pmid: 35552614 |
[16] | LEWITT P A, CHAUDHURI K R. Unmet needs in Parkinson disease: motor and non-motor[J]. Parkinsonism Relat Disord, 2020, 80 Suppl 1:S7-S12. |
[17] |
BANG Y, LIM J, CHOI H J. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment[J]. Arch Pharm Res, 2021, 44(6):588-604.
doi: 10.1007/s12272-021-01337-3 pmid: 34145553 |
[18] |
DU Y, LI Y, XU X, et al. Probiotics for constipation and gut microbiota in Parkinson's disease[J]. Parkinsonism Relat Disord, 2022, 103:92-97.
doi: 10.1016/j.parkreldis.2022.08.022 URL |
[19] |
CHEN Z, LI G, LIU J. Autonomic dysfunction in Parkinson's disease: Implications for pathophysiology, diagnosis, and treatment[J]. Neurobiol Dis, 2020, 134:104700.
doi: 10.1016/j.nbd.2019.104700 URL |
[20] | 阿地拉·艾尼瓦尔, 张拉, 蒋森, 等. α-突触核蛋白基因多态性与帕金森病的关联分析[J]. 重庆医科大学学报, 2021, 46(7):844-848. |
ADILA·A, ZHANG L, JIANG S, et al. Correlation between polymorphism of α-synuclein gene and Parkinson's disease[J]. J Chongqing Med Univ, 2021, 46(7):844-848. | |
[21] |
DAUVILLIERS Y, SCHENCK C H, POSTUMA R B, et al. REM sleep behaviour disorder[J]. Nat Rev Dis Primers, 2018, 4(1):19.
doi: 10.1038/s41572-018-0016-5 pmid: 30166532 |
[22] |
HU M T. REM sleep behavior disorder (RBD)[J]. Neurobiol Dis, 2020, 143:104996.
doi: 10.1016/j.nbd.2020.104996 URL |
[23] |
LIN Y Q, CHEN S D. RBD: a red flag for cognitive impairment in Parkinson's disease?[J]. Sleep Med, 2018, 44:38-44.
doi: 10.1016/j.sleep.2018.01.006 URL |
[24] |
ZHAO X, SHAO Z, ZHANG Y, et al. Ceruloplasmin in Parkinson's disease and the nonmotor symptoms[J]. Brain Behav, 2018, 8(6):e00995.
doi: 10.1002/brb3.2018.8.issue-6 URL |
[25] |
WANG B, WANG X P. Does ceruloplasmin defend against neurodegenerative diseases?[J]. Curr Neuropharmacol, 2019, 17(6):539-549.
doi: 10.2174/1570159X16666180508113025 pmid: 29737252 |
[26] |
GARDNER B, DIERIKS B V, CAMERON S, et al. Metal concentrations and distributions in the human olfactory bulb in Parkinson's disease[J]. Sci Rep, 2017, 7(1):10454.
doi: 10.1038/s41598-017-10659-6 pmid: 28874699 |
[27] |
ZUZUÁRREGUI J R P, DURING E H. Sleep issues in Parkinson's disease and their management[J]. Neurotherapeutics, 2020, 17(4):1480-1494.
doi: 10.1007/s13311-020-00938-y pmid: 33029723 |
[28] |
HELLMAN N E, GITLIN J D. Ceruloplasmin metabolism and function[J]. Annu Rev Nutr, 2002, 22:439-458.
pmid: 12055353 |
[29] | 张忠伟, 李杨飞, 潘璟琍, 等. 扩散峰度成像参数在帕金森病诊断中的价值研究[J]. 中华全科医学, 2020, 18(2):273-276. |
ZHANG Z W, LI Y F, PAN J L, et al. The value research of diffusion kurtosis imaging parameters in diagnosing Parkinson's disease[J]. Chin J General Pract, 2020, 18(2):273-276. |
[1] | 武冬冬, 李淑华, 苏闻, 刘银红, 陈海波, 陈頔. 抗帕金森病药物诱发5-羟色胺综合征1例[J]. 诊断学理论与实践, 2023, 22(03): 303-305. |
[2] | 武冬冬, 陈玉辉, 刘芳, 刘银红, 蒋景文. 脑小血管疾病合并中枢神经系统退行性疾病机制的研究进展[J]. 诊断学理论与实践, 2022, 21(05): 644-649. |
[3] | 何新, 陈慧, 冯炜炜. 机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546. |
[4] | 陈施吾, 窦荣花, 王玉凯, 王含, 王晓平, 陈先文, 陈玲, 王训, 屈洪党, 陈生弟, Susan Fox, 李燕, 王刚. 帕金森病血压管理专家共识[J]. 诊断学理论与实践, 2020, 19(05): 460-468. |
[5] | 邵丹丹, 付洋, 罗琪, 陈捷, 马建芳, 黄雷. 血清尿酸水平与帕金森病发病间关系的前瞻性研究[J]. 诊断学理论与实践, 2020, 19(02): 139-144. |
[6] | 武冬冬, 刘银红, 蒋景文, 陈海波. 放射性核素在帕金森病诊断中的应用[J]. 诊断学理论与实践, 2018, 17(06): 726-730. |
[7] | 刘春风, 徐兴, 沈赟. 多导睡眠监测在帕金森病伴发睡眠障碍诊断中的应用[J]. 诊断学理论与实践, 2018, 17(04): 377-381. |
[8] | 严振鹏, 杨月嫦, 吴惠涓, 陈坤, 徐云霞. 1例多方案评估帕金森病睡眠障碍治疗疗效的病例报告[J]. 诊断学理论与实践, 2018, 17(04): 457-459. |
[9] | 邹扬, 崔海伦, 胡勇博, 高颖, 张月琪, 陈生弟, 王刚. 运动诱发电位用于鉴别诊断原发性帕金森病和多系统萎缩的临床研究[J]. 诊断学理论与实践, 2018, 17(04): 409-413. |
[10] | 曹学兵, 曾玮琪, 徐岩. 帕金森病冻结步态诊疗研究进展[J]. 诊断学理论与实践, 2018, 17(04): 382-386. |
[11] | 崔海伦, 张一帆, 管晓军, 黄沛钰, 刘志蓉, 袁园, 刘晓云, 朱红灿, 曹学兵, 陈玲, 陈先文, 陈燕, 商慧芳, 杨任民, 陈生弟, 张敏鸣, 王刚. 帕金森病及相关运动障碍的神经影像学诊断专家共识[J]. 诊断学理论与实践, 2018, 17(04): 403-408. |
[12] | 崔诗爽, 陈生弟, 王刚. 帕金森病体液生物标志物研究进展[J]. 诊断学理论与实践, 2018, 17(04): 471-476. |
[13] | 贺娜英, 许洪敏, 黄沛, 陈生弟, 严福华, 凌华威. 基于定量磁化率图像观察帕金森病患者黑质体-1退变的研究[J]. 诊断学理论与实践, 2017, 16(02): 147-151. |
[14] | 沈博, 尤志菲, 王晓平,. 丘脑底核脑深部电刺激对帕金森病认知功能影响[J]. 诊断学理论与实践, 2016, 15(02): 128-132. |
[15] | 商慧芳, 陈永平,. 帕金森病生物标志物的研究现状及展望[J]. 诊断学理论与实践, 2016, 15(02): 92-95. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||